

HR 5657

Medical Marijuana Research Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 21, 2021

Current Status: Received in the Senate.

Latest Action: Received in the Senate. (Apr 5, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/5657>

Sponsor

Name: Rep. Blumenauer, Earl [D-OR-3]

Party: Democratic • **State:** OR • **Chamber:** House

Cosponsors (11 total)

Cosponsor	Party / State	Role	Date Joined
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Oct 21, 2021
Rep. Case, Ed [D-HI-1]	D · HI		Oct 21, 2021
Rep. Cohen, Steve [D-TN-9]	D · TN		Oct 21, 2021
Rep. Dingell, Debbie [D-MI-12]	D · MI		Oct 21, 2021
Rep. Griffith, H. Morgan [R-VA-9]	R · VA		Oct 21, 2021
Rep. Harris, Andy [R-MD-1]	R · MD		Oct 21, 2021
Rep. Lee, Barbara [D-CA-13]	D · CA		Oct 21, 2021
Rep. Joyce, David P. [R-OH-14]	R · OH		Feb 4, 2022
Rep. Pappas, Chris [D-NH-1]	D · NH		Mar 30, 2022
Rep. Mace, Nancy [R-SC-1]	R · SC		Apr 4, 2022
Rep. Perlmutter, Ed [D-CO-7]	D · CO		Apr 4, 2022

Committee Activity

Committee	Chamber	Activity	Date
Budget Committee	House	Referred To	Oct 21, 2021
Energy and Commerce Committee	House	Referred to	Oct 22, 2021
Judiciary Committee	House	Referred To	Oct 21, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Medical Marijuana Research Act

This bill establishes a new, separate registration process to facilitate medical marijuana research.

Specifically, it directs the Drug Enforcement Administration to register (1) practitioners to conduct medical marijuana research, and (2) manufacturers and distributors to supply marijuana for such research.

Additionally, the Department of Health and Human Services must continue to produce marijuana through the National Institute on Drug Abuse Drug Supply Program and implement a specialized process for supplying marijuana products available through state-authorized marijuana programs to researchers until manufacturers and distributors can provide a sufficient supply of marijuana for medical research.

Actions Timeline

- **Apr 5, 2022:** Received in the Senate.
- **Apr 4, 2022:** Mr. Pallone moved to suspend the rules and pass the bill, as amended.
- **Apr 4, 2022:** Considered under suspension of the rules. (consideration: CR H4136-4140)
- **Apr 4, 2022:** DEBATE - The House proceeded with forty minutes of debate on H.R. 5657.
- **Apr 4, 2022:** At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
- **Apr 4, 2022:** Considered as unfinished business. (consideration: CR H4144-4145)
- **Apr 4, 2022:** Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 343 - 75 (Roll no. 108).(text: CR H4136-4138)
- **Apr 4, 2022:** On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 343 - 75 (Roll no. 108). (text: CR H4136-4138)
- **Apr 4, 2022:** Motion to reconsider laid on the table Agreed to without objection.
- **Oct 22, 2021:** Referred to the Subcommittee on Health.
- **Oct 21, 2021:** Introduced in House
- **Oct 21, 2021:** Sponsor introductory remarks on measure. (CR E1126)
- **Oct 21, 2021:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.